Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epoetin delta

Drug Profile

Epoetin delta

Alternative Names: Dynepo; GA-EPO; Gene-activated epoetin alfa; Gene-activated epoetin alpha; Gene-activated erythropoietin; HMR 4396; MDL 104396; Recombinant human erythropoietin δ

Latest Information Update: 16 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis; Shire Pharmaceuticals Group
  • Developer sanofi-aventis; Shire; Shire plc
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Market Withdrawal Anaemia

Most Recent Events

  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 31 Dec 2008 Discontinued - Registered for Anaemia in European Union (IV)
  • 31 Dec 2008 Discontinued - Registered for Anaemia in European Union (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top